Forensic · IMMX

Immix Biopharma

12
MODERATE
12/100
1 signal from 0 red flags, 0 cyber, 1 dilution event

Top signals

Atm Offering Active
424B5 ATM offering prospectus in the last 6 months (active dilution).
+12

Bear case preview · free

Immix Biopharma is managing an active ATM offering that creates ongoing shareholder dilution risk, a signal that typically emerges when companies need to preserve cash runway without committing to fixed capital raises. The 424B5 prospectus filing indicates the company is drawing on this mechanism to fund operations, which warrants monitoring of burn rate against cash position and the pace of drawdowns. Watch for any acceleration in ATM utilization or guidance revisions regarding cash runway over the next 6-12 weeks, as these often precede material adverse announcements in early-stage biotech firms.

↑ That's free. The $9 report goes deeper: every filing cited by accession number, 36-month chronology, what to watch next.

What we checked

✓ Red flags · 36mo
0 8-K events (bankruptcy, delisting, restatement, auditor, officer)
✓ Cyber · 12mo
0 Item 1.05 disclosures + buried-cyber scan
✓ Dilution · 24mo
1 S-3 + 424B5 filing
✓ Buried events
Item 8.01 sections classified for hidden material disclosures
$9 · one-time · emailed in under a minute

The full bear case on IMMX

Plain-English brief. Every signal cited to the exact SEC filing. 36-month chronology. What changes next.

No-signals refund: if the algorithm finds zero red flags on your ticker, reply "refund" and I send the $9 back same day. No questions.

Not ready to buy? Get a free preview by email instead

We'll email you the top 3 signals on IMMX + a discount code for the full report. No subscription, no spam.

Share this score: X / Twitter

Score another ticker

Not investment advice. Every signal grounded in a specific SEC filing. Companies may respond via info@filingfirehose.com.